ClinicalTrials.gg
RecruitingNCT07343440OPTICalUpdated May 19, 2026

Trial on the Impact of Indirect Calorimetry-Guided Nutritional Support on Patient-Centered Outcomes in Critically Ill Patients - The OPTICal Study

An interventional study of Indirect Calorimetry Group and Control Group - Formula-Based Group in Critical Illness and ICU, sponsored by HEIDEGGER CP. Recruiting at 3 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by HEIDEGGER CP · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This multicentric randomized controlled trial aims to evaluate whether indirect calorimetry (IC)-guided nutritional support improves patient-centered outcomes in critically ill adult patients compared to standard formula-based nutritional strategies. The study includes mechanically ventilated patients expected to remain in the ICU for more than 72 hours. The intervention group will receive nutritional targets based on measured resting energy expenditure using the QNRG+ device, with a gradual escalation of energy delivery following current ESPEN guidelines. The primary outcome is quality of life at 3 months post-ICU admission, assessed using the EQ-5D-5L. Secondary outcomes include functional recovery, muscle preservation, infection rates, and rehospitalization. This study is the first to assess the long-term impact of IC-guided nutrition on recovery and quality of life using a patient-centered approach.

02

Conditions studied

  • Critical Illness
  • ICU

Browse trials for

Keywords

  • Nutrition
  • Indirect calorimetry
  • Nutrition therapy
  • Predictive formula
03

In context

Critical Illness

1,787 studies on the registry are indexed under Critical Illness; 445 are open to participants now.

This study's planned enrollment of 356 is above the median of 90 across 930 interventional studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

HEIDEGGER CP is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All patients admitted to the ICU with the following criteria:

  • ≥18 years old
  • On Mechanical Ventilation
  • Expected ICU length of stay >72 hours

Exclusion criteria

Exclusion Criteria:

  • Refusal of the family or patient
  • Patient transferred from another ICU
  • Pregnant patient
  • Patient is planned for a withdrawal of care or is actively dying
  • Cognitive disorder before ICU
  • Patient is in jail
  • Patients already enrolled in the ongoing NutriPhyT trial
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
356 participants (estimated)

Study arms

  • Experimental
    Intervention Group - Indirect Calorimetry Group

    Other: Indirect Calorimetry Group

  • Active comparator
    Control Group - Formula-Based Group

    Other: Control Group - Formula-Based Group

Interventions

  • OtherIndirect Calorimetry Group

    * Nutritional targets measured by IC starting on Day 4 * Repeated IC measurements 2 times weekly performed with the QNRG+ device * Gradual escalation to 80%-100% caloric coverage by Day 4

  • OtherControl Group - Formula-Based Group

    * Nutritional targets determined using predictive equations (pragmatic, set at local level) * Escalation as per local protocol

06

What researchers measure

Primary outcomes

  1. Quality of life (EQ-5D-5L)

    Measured using the EQ-5D-5L: 0-100

    Time frame: At 3 months after ICU admission

Secondary outcomes

  1. Mortality

    Time frame: Up to 3 months after ICU admission

  2. Nosocomial infection

    Defined as the initiation of a new antibiotic treatment lasting at least 72 hours, associated with a documented diagnosis of infection in the patient's chart

    Time frame: Up to 28 days after ICU admission

  3. Pressure soar

    Time frame: Up to 28 days after ICU admission

  4. Energy deficit in kcal

    according to the energy target defined by IC or predictive formula depending on the randomization group

    Time frame: Up to 28 days after ICU admission

  5. Protein deficit in grams

    according to the protein target defined by predictive formula

    Time frame: Up to 28 days after ICU admission

  6. Ventilation-free days

    Time frame: Measured at day 28 after ICU admission

  7. ICU free-days

    Time frame: Measured at day 28 after ICU admission

  8. Functional recovery: Bartel Index

    Using Barthel Index: 0-100

    Time frame: At ICU discharge or up to 28 days after ICU admission and at 3 months after ICU discharge

  9. Gerneral well-being: Edmonton Symptom Assessment Scale

    Using Edmonton Symptom Assessment Scale (ESAS) : 0-90

    Time frame: At ICU discharge or up to 28 days after ICU admission and at 3 months after ICU discharge

  10. Readmission and rehospitalization rates

    Time frame: Until 3-month post-ICU admission

  11. Discharge place

    Time frame: Until 3 months after ICU admission

  12. Return to work

    Time frame: Until 3 months after ICU admission

  13. Disability and functioning: WHO Disability Assessment Schedule

    Using WHO Disability Assessment Schedule (WHODAS 2.0): 0-48

    Time frame: At 3-month post ICU admission

  14. Disability and functioning: Clinical Frailty Scale

    Using Clinical Frailty Scale (CFS): 1-9

    Time frame: At 3-month post ICU admission

  15. Disability and functioning: Short-form 12

    Using Short-form 12 (SF-12): 0-100

    Time frame: At 3-month post ICU admission

  16. Disability and functioning: MOCA-5

    Using montreal cognitive assessment- 5 min (MOCA-5): 0-15

    Time frame: At 3-month post ICU admission

  17. Disability and functioning: Patient Health Questionnaire-9

    Using Patient Health Questionnaire-9 (PHQ-9): 0-27

    Time frame: At 3-month post ICU admission

07

Study locations

3 of 3 sites recruiting
  • Geneva University Hospital
    Geneva, Switzerland
    Recruiting
    • Claudia Paula Heidegger, Prof. · Contactclaudia.heidegger@hug.ch · +41223727440
    • Aude de Watteville, MSc · Contactaude.dewatteville@hug.ch · +41795533998
    • Claudia Heidegger, Prof. · Principal investigator
    • Hannah Wozniak, Dr. med · Sub investigator
    • Aude de Watteville, MSc · Sub investigator
  • GHOL
    Nyon, Switzerland
    Recruiting
  • Zürich University Hospitals
    Zurich, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

Of 405 non-industry interventional studies with no phase under Critical Illness, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 17 months is below that.

Counting every sponsor, half of 409 studies reached it within 21 months; a quarter within 11 and three quarters within 40.

Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Jan 15, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Sep 1, 2027
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07343440
Lead sponsor
HEIDEGGER CP
Collaborators
University Hospital, Zürich, GHOL Nyon Hospital
Responsible party
HEIDEGGER CP (Prof, University Hospital, Geneva) — Sponsor-investigator
First posted
Jan 15, 2026
Start date
Jan 1, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
May 19, 2026

Study contacts

Claudia Paula Heidegger, Prof.
Contact
claudia.heidegger@hug.ch
+41223727440
Aude de Watteville, MSc
Contact
aude.dewatteville@hug.ch
+41795533998

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion